Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTR003 PET Imaging for Myocardial Viability in Ischemic Cardiomyopathy
NCT07443696Phase 2Recruiting
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Dec 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of XTR003 in ischemic cardiomyopathy (ICM) and heart failure (HF), sponsored by Sinotau Pharmaceutical Group. Primary endpoints: Sensitivity of PET Myocardial Metabolic Imaging at 6 months and Specificity of PET Myocardial Metabolic Imaging at 6 months. Started Dec 2025; status: recruiting.
02
Drugs
XTR003
03
Conditions
ischemic cardiomyopathy (ICM)heart failure (HF)
Beyond the preview
Go deeper on NCT07443696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07443696.